Research programme: inflammatory diseases therapeutics and companion diagnostics - Neutrolis
Latest Information Update: 28 Dec 2021
At a glance
- Originator Neutrolis Therapeutics
- Class Anti-inflammatories; Diagnostic agents
- Mechanism of Action Neutrophil inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sepsis; Systemic lupus erythematosus
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Sepsis in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Sepsis(Diagnosis) in USA
- 28 Dec 2021 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA